

1 **DRAFT SCIENTIFIC OPINION**

2 **Scientific Opinion on Dietary Reference Values for biotin<sup>1</sup>**

3 **EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA)<sup>2,3</sup>**

4 European Food Safety Authority (EFSA), Parma, Italy

5 **ABSTRACT**

6 Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies  
7 (NDA) derived Dietary Reference Values (DRVs) for biotin. Biotin is a water-soluble vitamin, which serves as a  
8 co-factor for several carboxylases that play critical roles in the synthesis of fatty acids, the catabolism of  
9 branched-chain amino acids and gluconeogenesis. Dietary biotin deficiency is rare. Data on biomarkers of biotin  
10 intake or status are insufficient to be used in determining the requirement for biotin. Data available on biotin  
11 intakes and health consequences are very limited and cannot be used for deriving DRVs for biotin. As there is  
12 insufficient evidence available to derive an Average Requirement and a Population Reference Intake, an  
13 Adequate Intake (AI) is proposed. The setting of AIs is based on observed biotin intakes with a mixed diet and  
14 the apparent absence of signs of deficiency in the EU, suggesting that current intake levels are adequate. The AI  
15 for adults is set at 40 µg/day. The AI for adults also applies to pregnant women. For lactating women, an  
16 additional 5 µg biotin/day to the AI for adults is proposed, to compensate for biotin losses through breast milk.  
17 For infants over six months, an AI of 6 µg/day is proposed by extrapolating from the biotin intake of exclusively  
18 breast-fed infants aged zero to six months, using allometric scaling based on reference body weights of the  
19 respective age groups, in order to account for the role of biotin in energy metabolism. The AI for children aged  
20 1–3 and 4–10 years are set at 20 and 25 µg/day, respectively, and for adolescents at 35 µg/day, based on  
21 observed intakes in the EU.

22 © European Food Safety Authority, 20YY

23 **KEY WORDS**

24 biotin, Dietary Reference Value, Adequate Intake

---

<sup>1</sup> On request from the European Commission, Question No EFSA-Q-2011-01205, endorsed for public consultation on 11 October 2013

<sup>2</sup> Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen. Correspondence: [nda@efsa.europa.eu](mailto:nda@efsa.europa.eu)

<sup>3</sup> Acknowledgement: The Panel wishes to thank the members of the Working Group on Dietary Reference Values for vitamins: Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Hildegard Przyrembel, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé and Dominique Turck for the preparatory work on this scientific opinion.

Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 20YY. Scientific Opinion on Dietary Reference Values for biotin. EFSA Journal 20YY;volume(issue):NNNN, 25 pp. doi:10.2903/j.efsa.20YY.NNNN

Available online: [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal)

## 26 SUMMARY

27 Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition  
28 and Allergies (NDA) was asked to deliver a scientific opinion on Dietary Reference Values (DRVs)  
29 for the European population, including biotin.

30 In 1993, the Scientific Committee for Food proposed an Acceptable Range of Intakes of biotin for  
31 adults of 15–100 µg/day, based on observed intakes of biotin in European countries, which were  
32 considered adequate to meet requirements and prevent deficiency.

33 Biotin is a water-soluble vitamin, which serves as a co-factor for several carboxylases that play critical  
34 roles in the synthesis of fatty acids, the catabolism of branched-chain amino acids and  
35 gluconeogenesis. Dietary biotin deficiency is rare.

36 Free biotin is absorbed nearly completely, while there is a lack of data on the absorption of protein-  
37 bound biotin from foods. In the cell, biotin is covalently attached to biotin-dependent carboxylases  
38 from which it can be released by other enzymes, or, alternatively, is catabolised through different  
39 pathways. Biotin and its metabolites are excreted in the urine.

40 The Panel notes that biomarkers sensitive to biotin depletion have been identified. These include  
41 urinary biotin excretion and biomarkers of biotin function, such as urinary excretion of 3-  
42 hydroxyisovaleric acid (3HIA), 3HIA-carnitine, activity of propionyl-CoA carboxylase and abundance  
43 of biotinylated β-methylcrotonyl-CoA carboxylase and propionyl-CoA carboxylase in lymphocytes.  
44 However, data from the general population are limited so that the variability characteristics of these  
45 biomarkers and their ability to discriminate between biotin insufficiency and adequacy are not well  
46 known. Dose-response relationships between biotin intakes and these biomarkers have not been  
47 established. The Panel considers that data are insufficient to derive the AR for biotin from the use of  
48 available biomarkers of intake or status for any population group.

49 Data available on biotin intakes and health consequences are very limited and cannot be used for  
50 deriving DRVs for biotin.

51 As the evidence to derive an Average Requirement and thus a Population Reference Intake is  
52 considered insufficient, an Adequate Intake (AI) is proposed for all population groups. There is no  
53 indication that the AI should be different according to sex. The setting of AIs is based on observed  
54 biotin intakes with a mixed diet and the apparent absence of signs of deficiency in the EU, suggesting  
55 that current intake levels are adequate. Estimates of the biotin content of foods vary widely, due both  
56 to natural variation and to the analytical method used, and this contributes to uncertainty regarding  
57 current intake estimates. Estimates of biotin intakes in children, adolescents, adults and older adults  
58 were available from five EU countries. In boys and girls (5–12 years) in the EU, mean/median intakes  
59 ranged from 19 to 38 µg/day, while mean/median intakes between 17 and 64 µg/day were reported for  
60 adolescent boys and girls (13–19 years). In adult men and women below about 65 years, mean/median  
61 intakes ranged from 26 to 50 µg/day, while mean/median intakes between 24 and 43 µg/day were  
62 reported for older adult men and women.

63 The AI for adults is set at 40 µg/day. The AI for adults also applies to pregnant women. For lactating  
64 women, an additional 5 µg/day to the AI for adults is proposed, to compensate for biotin losses  
65 through breast milk. For infants over six months, an AI of 6 µg/day is proposed by extrapolating from  
66 the biotin intake of exclusively breast-fed infants aged zero to six months, using allometric scaling  
67 based on reference body weights of the respective age groups to the power of 0.75, in order to account  
68 for the role of biotin in energy metabolism, and rounding to the nearest unit. The AI for children aged  
69 1–3 and 4–10 years are set at 20 and 25 µg/day, respectively, and for adolescents at 35 µg/day, based  
70 on observed intakes in the EU.

71	<b>TABLE OF CONTENTS</b>	
72	Abstract .....	1
73	Key words .....	1
74	Summary .....	2
75	Table of contents .....	3
76	Background as provided by the European Commission.....	4
77	Terms of reference as provided by the European Commission.....	4
78	Assessment .....	6
79	1. Introduction .....	6
80	2. Definition/category .....	6
81	2.1. Chemistry .....	6
82	2.2. Function, physiology and metabolism .....	6
83	2.3. Biomarkers .....	7
84	3. Dietary sources and intake data .....	8
85	3.1. Dietary sources.....	8
86	3.2. Dietary intakes .....	9
87	4. Overview of Dietary Reference Values and recommendations .....	10
88	4.1. Adults.....	10
89	4.2. Infants and children.....	10
90	4.3. Pregnancy and lactation .....	10
91	5. Criteria (endpoints) on which to base Dietary Reference Values.....	11
92	5.1. Indicators of biotin requirement.....	11
93	5.2. Biotin intake and health consequences .....	11
94	5.3. Specific considerations for pregnancy and lactation.....	12
95	6. Data on which to base Dietary Reference Values.....	12
96	6.1. Adults.....	12
97	6.2. Infants, children and adolescents .....	12
98	6.3. Pregnancy and lactation .....	13
99	Conclusions .....	13
100	Recommendations for research .....	13
101	References .....	13
102	Appendices .....	19
103	Appendix A. Biotin concentration of human milk from healthy mothers of term infants .....	19
104	Appendix B. Biotin intake among children and adolescents in European countries .....	20
105	Appendix C. Biotin intake among adults aged ~ 19–65 years in European countries.....	22
106	Appendix D. Biotin intake among adults aged ~ 65 years and over in European countries.....	23
107	Abbreviations .....	24

108

## 109 BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

110 The scientific advice on nutrient intakes is important as the basis of Community action in the field of  
111 nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The  
112 Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European  
113 Community dates from 1993. There is a need to review and if necessary to update these earlier  
114 recommendations to ensure that the Community action in the area of nutrition is underpinned by the  
115 latest scientific advice.

116 In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community<sup>4</sup>.  
117 The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did  
118 not include certain substances of physiological importance, for example dietary fibre.

119 Since then new scientific data have become available for some of the nutrients, and scientific advisory  
120 bodies in many European Union Member States and in the United States have reported on  
121 recommended dietary intakes. For a number of nutrients these newly established (national)  
122 recommendations differ from the reference intakes in the SCF (1993) report. Although there is  
123 considerable consensus between these newly derived (national) recommendations, differing opinions  
124 remain on some of the recommendations. Therefore, there is a need to review the existing EU  
125 Reference Intakes in the light of new scientific evidence, and taking into account the more recently  
126 reported national recommendations. There is also a need to include dietary components that were not  
127 covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be  
128 appropriate to establish reference intakes for other (essential) substances with a physiological effect.

129 In this context the EFSA is requested to consider the existing Population Reference Intakes for energy,  
130 micro- and macronutrients and certain other dietary components, to review and complete the SCF  
131 recommendations, in the light of new evidence, and in addition advise on a Population Reference  
132 Intake for dietary fibre.

133 For communication of nutrition and healthy eating messages to the public it is generally more  
134 appropriate to express recommendations for the intake of individual nutrients or substances in food-  
135 based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient  
136 based recommendations for a healthy diet into food based recommendations intended for the  
137 population as a whole.

## 138 TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

139 In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No 178/2002, the Commission  
140 requests EFSA to review the existing advice of the Scientific Committee for Food on population  
141 reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in  
142 the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good  
143 health through optimal nutrition.

144 In the first instance the EFSA is asked to provide advice on energy, macronutrients and dietary fibre.  
145 Specifically advice is requested on the following dietary components:

- 146 • Carbohydrates, including sugars;
- 147 • Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty  
148 acids, *trans* fatty acids;
- 149 • Protein;

---

<sup>4</sup> Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific Committee for Food 31<sup>st</sup> series, Office for Official Publication of the European Communities, Luxembourg, 1993.

150 • Dietary fibre.

151 Following on from the first part of the task, the EFSA is asked to advise on population reference  
152 intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a  
153 nutritional or physiological effect in the context of a balanced diet which, when part of an overall  
154 healthy lifestyle, contribute to good health through optimal nutrition.

155 Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into  
156 guidance, intended for the European population as a whole, on the contribution of different foods or  
157 categories of foods to an overall diet that would help to maintain good health through optimal nutrition  
158 (food-based dietary guidelines).

159

160 **ASSESSMENT**161 **1. Introduction**

162 In 1993, the Scientific Committee for Food (SCF) adopted an opinion on the nutrient and energy  
163 intakes for the European Community but was unable to define a specific physiological requirement of  
164 biotin for human health (SCF, 1993). The SCF noted that average intakes in adults in the European  
165 Community were about 28–42 µg/day, but that individuals consumed 15–100 µg/day. The SCF  
166 proposed an Acceptable Range of Intakes of biotin for adults of 15–100 µg/day, which was considered  
167 adequate to meet requirements and prevent deficiency. The SCF considered that there was no  
168 information on which to base additional requirements for biotin in pregnancy or lactation. The SCF  
169 did not set reference values for infants and children.

170 **2. Definition/category**171 **2.1. Chemistry**

172 Biotin (also called vitamin H or vitamin B7) is a bicyclic water-soluble vitamin that comprises an  
173 ureido ring fused with tetrahydrothiophene ring, which contains a sulphur atom and a valeric acid side  
174 chain (Mock, 2006). It has a molecular mass of 244.31 Da. The only form found in nature that is  
175 biologically active is the isomer D(+)-biotin (Mock, 2006).

176 Biotin in food and human tissues may occur in the free form or protein-bound form. Microbiological  
177 assays and avidin-binding assays have most frequently been used to quantify biotin in foods and  
178 biological fluids. Assays need to account for interferences of biotin analogues and metabolites, as well  
179 as the need for prior acid or enzymatic hydrolysis necessary to measure protein-bound biotin (Mock  
180 and Malik, 1992; Lahely et al., 1999), which affect their specificity and sensitivity. Thus, both natural  
181 variation and analytical aspects may account for the variability of reported biotin concentrations in  
182 foods or body fluids and it is important to establish how biotin was quantified when comparing studies  
183 (SCF, 2001).

184 High performance liquid chromatography (HPLC)/avidin-binding assay is considered the most  
185 accurate and sensitive assay for quantification of biotin (IOM, 1998; SCF, 2001; Staggs et al., 2004).

186 **2.2. Function, physiology and metabolism**

187 Biotin is a co-factor for the enzymes acetyl-CoA carboxylase (ACC), propionyl-CoA carboxylase  
188 (PCC), β-methylcrotonyl-CoA carboxylase (MCC) and pyruvate carboxylase (PC), which play critical  
189 roles in the synthesis of fatty acids, the catabolism of branched-chain amino acids and  
190 gluconeogenesis (Zempleni and Mock, 1999c). Humans cannot synthesise biotin and depend on its  
191 dietary intake.

192 At usual intakes, free biotin is absorbed nearly completely through a saturable carrier-mediated  
193 process. Absorption efficiency of free biotin is also high upon ingestion of large doses (up to  
194 20 mg/day) due to passive diffusion taking place (Zempleni and Mock, 1999b). Protein-bound biotin  
195 requires to be released by biotinidase before absorption. The proportion of free biotin versus protein-  
196 bound biotin varies among foods; the majority of biotin in meats and cereals is protein-bound  
197 (Zempleni and Mock, 1999c). There is a lack of data on the level of absorption of protein-bound biotin  
198 from foods. Avidin, a protein found in raw egg white, has a very high affinity for biotin and prevents  
199 its absorption in the small intestine. Faecal excretion of biotin has been observed to be three to six  
200 times higher than intakes, due to the production of large amounts of biotin by the intestinal microbiota;



201 however, the extent to which biotin is absorbed from the large intestine and contributes to biotin  
202 requirements is uncertain (SCF, 2001).

203 Once in plasma, biotin is transported as free biotin (81 %), as well as covalently or reversibly bound to  
204 plasma proteins (12 % and 7 %, respectively) (Mock, 2006). Biotin uptake into the liver and peripheral  
205 tissues occurs via a specific sodium-dependent, carrier-mediated process and by diffusion. In the cell,  
206 biotin is covalently attached to biotin-dependent carboxylases. Holocarboxylases can be degraded to  
207 biocytin or biotin-containing oligopeptides from which biotin can be released by biotinidase and re-  
208 used in the metabolism. The biotin that is not incorporated into carboxylase enzymes is catabolised  
209 through different pathways to form bisnorbiotin, tetranorbiotin and related intermediates, by  $\beta$ -  
210 oxidation of the valeric side-chain, or biotin sulphoxides and sulphone, by oxidation of the sulphur  
211 present in its heterocyclic ring (Mock, 2006). Biotin and its metabolites are excreted in the urine  
212 (Mock NI et al., 1997; Zempleni et al., 1997b). Biliary excretion of biotin and its metabolites is  
213 thought to be quantitatively negligible (Zempleni and Mock, 1999a), as indicated by data in rats and  
214 pigs (Zempleni et al., 1997a). Biotin metabolites do not have vitamin activity.

215 Placental transport of biotin involves an active mechanism (Grassl, 1992; Wang et al., 1999; Mock,  
216 2006); from the second trimester, biotin concentrations have been observed to be 3- to 17-fold higher  
217 in the plasma of fetuses compared to plasma of their mothers (Mantagos et al., 1998).

218 The concentration of biotin in human milk has been observed to vary significantly among subjects,  
219 over the course of the day and as a function of time *post partum* (Mock et al., 1992; Mock DM et al.,  
220 1997b). Mean concentrations of biotin in mature human milk measured by microbiological assays  
221 typically range between about 4 and 6  $\mu\text{g/L}$  (data from Finland, UK, Japan and the US, up to one year  
222 of lactation) (Goldsmith et al., 1982; Ford et al., 1983; Salmenpera et al., 1985; Hirano et al., 1992;  
223 Sakurai et al., 2005) (Appendix A). Using an HPLC/avidin-binding assay, Mock DM et al. (1997b)  
224 reported mean biotin concentrations in mature milk of around 7  $\mu\text{g/L}$  in a cohort of 15 healthy breast-  
225 feeding women in the US, which were not consuming daily supplements containing more than 4  $\mu\text{g}$   
226 biotin (about 10 % of daily intake).

227 Dietary biotin deficiency is rare and is characterised by fine scaly dermatitis, hair loss, conjunctivitis,  
228 ataxia and delayed child development (Zempleni and Mock, 1999c). Cases of biotin deficiency have  
229 been observed in patients receiving long-term total parenteral nutrition without biotin supplementation  
230 and patients with biotinidase deficiency, as well as in people who had consumed large amounts of raw  
231 eggs (Zempleni and Mock, 1999c). Biotin deficiency during pregnancy has been shown to be  
232 teratogenic in several species, including mice, hamsters, chicken and turkeys (Said, 1999; Zempleni  
233 and Mock, 2000; Mock, 2005), but no data are available in humans indicative of an association  
234 between biotin deficiency in pregnancy and an increased incidence of fetal malformations.

235 The SCF could not derive a Tolerable Upper Intake Level (UL) and stated that available evidence  
236 indicates that observed levels of intake of biotin from all sources do not represent a health risk for the  
237 general population (SCF, 2001).

238 Although biotin and pantothenic acid have been shown to share common carrier-mediated uptake  
239 mechanisms *in vitro* (Said, 2009), nutritional implications of this interaction are not known.

### 240 **2.3. Biomarkers**

241 Mock and his collaborators have studied urinary and blood biomarkers of biotin status by providing  
242 healthy men and women with a biotin-depleted diet based on raw egg white, to induce asymptomatic  
243 biotin insufficiency. Between seven and 11 subjects were involved in each study and depletion lasted  
244 for three to four weeks. The 24-hour urinary excretion of biotin was found to decrease significantly  
245 over the depletion period (Mock NI et al., 1997; Mock et al., 2002a), while plasma concentration of  
246 biotin was not significantly affected (Mock NI et al., 1997). Biotin insufficiency was also shown to

247 affect markers of the activities of biotin-dependent carboxylase enzymes and related metabolic  
 248 pathways. The 24-hour urinary excretion of 3-hydroxyisovaleric acid (3HIA) and 3HIA-carnitine, as  
 249 well as fasting plasma 3HIA-carnitine concentration, were found to increase significantly in male and  
 250 female subjects over the depletion period, indicating a reduced activity of MCC (Mock NI et al., 1997;  
 251 Mock et al., 2002a; Horvath et al., 2010a; Horvath et al., 2010b; Stratton et al., 2011). Pooling of data  
 252 from two sources (Mock et al., 2002a; Mock et al., 1997c) indicated that urinary excretion of 3HIA or  
 253 biotin did not differ between sexes, neither before egg white feeding nor at day 21 of depletion (Mock  
 254 et al., 2002a). Urinary excretion of 3HIA and 3HIA-carnitine was also shown to significantly increase  
 255 in response to an oral challenge of leucine, an amino-acid whose degradation requires MCC (Mock et  
 256 al., 2002a; Mock et al., 2011). A decrease in PCC activity in lymphocytes and, more recently, an  
 257 increase in the ratios of acylcarnitines in urine, arising from acyl-CoA substrates and their products,  
 258 which reflect disturbances in biotin-dependent carboxylase activities, were also observed in response  
 259 to induced biotin insufficiency (Stratton et al., 2006; Bogusiewicz et al., 2012).

260 In a randomised cross-over study in 16 healthy non-smoking men and women (21–45 years) possible  
 261 markers of biotin status were assessed. Each subject followed three intervention phases of three weeks  
 262 each interrupted by wash-out periods of two weeks, i.e. biotin “depletion” (using an egg white diet),  
 263 “sufficiency” (habitual diet supplemented with 30 µg/day of biotin) and “supplementation” (habitual  
 264 diet supplemented with 600 µg/day of biotin) (Eng et al., 2013). Significant differences in the amounts  
 265 of biotinylated MCC and PCC in lymphocytes were observed between the three interventions. Urinary  
 266 excretion of biotin did not differ between the “biotin deficient” and “biotin sufficient” interventions.  
 267 Urinary excretion of 3HIA was twice higher during the “biotin deficient” intervention than during the  
 268 two other interventions. However, for eight of the 16 subjects, the urinary excretion of 3HIA did not  
 269 increase during biotin “depletion” compared with the other intervention periods. The amount of  
 270 mRNAs coding for biotin-dependent carboxylases, biotin transporters and holocarboxylase synthetase  
 271 in lymphocytes was not different among the interventions.

272 Smoking (Sealey et al., 2004) and the use of some anticonvulsant drugs (Mock and Dyken, 1997;  
 273 Mock et al., 1998) were also found to increase urinary excretion of 3HIA and to increase ratios of  
 274 urinary biotin catabolites to biotin, indicating increased catabolism of biotin.

275 The Panel notes that biomarkers sensitive to biotin depletion have been identified in adults. These  
 276 include urinary biotin excretion and biomarkers of biotin function, such as urinary excretion of 3HIA  
 277 and 3HIA-carnitine, and PCC activity and abundance of biotinylated MCC and PCC in lymphocytes.  
 278 However, data from the general population are limited so that the variability characteristics of these  
 279 biomarkers and their ability to discriminate between biotin insufficiency and adequacy are not well  
 280 known. Dose-response relationships between biotin intakes and these biomarkers have not been  
 281 established.

### 282 3. Dietary sources and intake data

#### 283 3.1. Dietary sources

284 Staggs et al. (2004) compared the biotin content of 87 foods using an HPLC/avidin-binding assay to  
 285 values published from earlier analyses, mostly using bioassays. Although this study confirmed  
 286 previous assessments that meat, fish, poultry, egg, some cheeses and some vegetables are rich dietary  
 287 sources of biotin. The HPLC/avidin-binding assay showed that liver (416 ng/g of wet weight), eggs  
 288 (214 ng/g of wet weight), and mushrooms (22 ng/g of wet weight), as well as some cheeses (15–30  
 289 ng/g of wet weight) were the richest sources of biotin, while smaller amounts were contained in lean  
 290 meat, fruit, cereals and bread (1–10 ng/g of wet weight). Most previously published values were  
 291 higher than those measured by the HPLC/avidin-binding assay. Differences may relate to the natural  
 292 variation of biotin content of foods (depending on, for instance, growing conditions, season,  
 293 geographic origin, processing), as well as to differences in the specificity and sensitivity of the  
 294 HPLC/avidin-binding assay and bioassays inherent to these methodologies (see Section 2.1.).



295 Currently, D-biotin may be added to foods<sup>5</sup> and food supplements.<sup>6</sup> The biotin content of infant and  
 296 follow-on formulae is regulated.<sup>7</sup>

### 297 **3.2. Dietary intakes**

298 Estimates of biotin intakes in children, adolescents, adults and older adults from five EU countries  
 299 (Austria, Germany, Hungary, Ireland and Latvia, data collected between 2003 and 2010) are provided  
 300 in Appendices B, C and D, respectively. Values were calculated from individual consumption data  
 301 collected from dietary history, three-/four-day dietary records, or 24-hour recall, combined with  
 302 analytical data from food composition tables. Dietary intake data are prone to reporting errors and  
 303 there is a varying degree of under-reporting in different surveys (Merten et al., 2011). Although the  
 304 differences in methodologies have an impact on the accuracy of between-country comparisons, the  
 305 data presented give an overview of the biotin intake in a number of European countries.

306 In young children (1–4 years) in the EU, median intakes ranged from 19 to 28 µg/day. A median  
 307 biotin intake of 19 µg/day was observed in Irish boys and girls (IUNA, online-e). Median biotin  
 308 intakes of 25 µg/day and 28 µg/day were observed in German girls and boys, respectively (DGE,  
 309 2012).

310 In boys and girls (5–12 years) in the EU, mean/median intakes ranged from 19 to 38 µg/day. Median  
 311 intakes ranged from 19 to 24 µg/day in Ireland (boys and girls, 5–12 years), and were reported to be  
 312 36 µg/day in girls and 38 µg/day in boys in Germany (6–11 years), while mean intakes ranged from 30  
 313 to 35 µg/day in Austria (boys and girls, 7–12 years).

314 In adolescent boys and girls (13–19 years), mean/median intakes ranged from 17 to 64 µg/day. Median  
 315 intakes ranged from 17 to 27 µg/day in Ireland (boys and girls, 13–19 years) and were reported to be  
 316 36 µg/day in girls and 45 µg/day in boys (15–19 years, determined by 24-hour recall) or 50 µg/day in  
 317 girls and 64 µg/day in boys (12–17 years, using dietary history over four weeks) in Germany. Mean  
 318 intakes ranged from 31 to 47 µg/day in Austria (13–19 years).

319 In adult men and women below ~ 65 years, mean/median intakes ranged from 26 to 50 µg/day. Data  
 320 from Germany and Ireland indicated median intakes between 40 and 48 µg/day in men and 29 and 42  
 321 µg/day in women, while mean intakes were observed to range between 33 and 50 µg/day in men and  
 322 26 and 43 µg/day in women in Hungary and Austria, and between 34 and 45 µg/day for both sexes in  
 323 Latvia.

324 In older adult men and women in the EU, mean/median intakes ranged from 24 to 43 µg/day. Median  
 325 intakes between 36 and 43 µg/day in men and 32 and 39 µg/day in women were observed in Germany  
 326 and Ireland and mean intakes of 29 to 34 µg/day in men and 24 to 34 µg/day in women were reported  
 327 in Hungary and Austria.

328 Data on biotin intakes in pregnancy are scarce. Using a 24-hour recall, mean intakes of 49 µg/day and  
 329 48 µg/day were reported in 87 Viennese and 426 Austrian pregnant women, respectively (Elmadfa et  
 330 al., 2004; Elmadfa et al., 2009). Some intake estimates are also available from an observational study  
 331 conducted in the UK, where mean intakes of biotin in a population of 123 pregnant women were  
 332  $18 \pm 7$  µg/day (range: 5–37 µg/day), using a FFQ, and  $19 \pm 10$  µg/day (range: 5–79 µg/day), using 24-  
 333 hour recall (Mouratidou et al., 2006).

<sup>5</sup> Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods, OJ L 404, 30.12.2006, p. 26.

<sup>6</sup> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements, OJ L 183, 12.7.2002, p. 51.

<sup>7</sup> Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC, OJ L 401, 30.12.2006, p.1.

334 The Panel notes that estimates of the biotin content of foods vary widely, due both to natural variation  
335 and to the analytical method used (see Sections 2.1. and 3.1.), and that this contributes to uncertainty  
336 regarding current intake estimates.

#### 337 **4. Overview of Dietary Reference Values and recommendations**

338 Several national and international organisations and authorities have proposed reference values or  
339 recommendations for biotin intakes. There has been consensus so far that evidence is lacking to  
340 establish an Average Requirement (AR) for biotin. Rather, Adequate or Acceptable Ranges of Intakes  
341 have been proposed (Table 1). The Nordic countries did not set a reference value for biotin (NNR,  
342 2012).

##### 343 **4.1. Adults**

344 The SCF (1993) and the UK Committee on Medical Aspects of Food Policy (COMA) (DH, 1991) set  
345 Acceptable Ranges of Intakes, and the French Food Safety Agency (Afssa, 2001a) and the German-  
346 speaking countries (D-A-CH, 2013) set Adequate Intakes (AIs), based on data from dietary intake  
347 surveys, considering the absence of deficiency at observed intakes. The US Institute of Medicine  
348 (IOM, 1998) and the World Health Organization/Food and Agriculture Organization (WHO/FAO,  
349 2004) proposed AIs derived from upward extrapolation of the AI for infants using body weight to the  
350 power of 0.75 and respective reference body weights (allometric scaling).

##### 351 **4.2. Infants and children**

352 The German-speaking countries (D-A-CH, 2013), WHO/FAO (2004), Afssa (2001a) and IOM (1998)  
353 proposed AIs for infants based on typical biotin intakes with human milk in exclusively breast-fed  
354 infants. WHO/FAO (2004) and IOM (1998) derived AIs for children and adolescents from upward  
355 extrapolation of the AI for infants using body weight to the power of 0.75 and respective reference  
356 weights (allometric scaling), while Afssa (2001a) scaled down from the AI for adults using height  
357 squared as the basis for extrapolation.

##### 358 **4.3. Pregnancy and lactation**

359 Although an increase of urinary excretion of 3HIA and a decrease of urinary excretion of biotin have  
360 been observed in some pregnant women (Mock and Stadler, 1997; Mock DM et al., 1997a), data have  
361 been considered insufficient to derive a specific reference value for pregnant women (IOM, 1998;  
362 Afssa, 2001a; WHO/FAO, 2004). The AI set for adults was considered to be sufficient to cover the  
363 period of pregnancy.

364 An additional intake of 5 µg/day has generally been proposed for lactating women to cover biotin  
365 losses due to breastfeeding, considering the amount of biotin that would be excreted by women  
366 breastfeeding exclusively (IOM, 1998; Afssa, 2001b; WHO/FAO, 2004).

367 **Table 1:** Overview of Dietary Reference Values for biotin

	<b>D-A-CH (2013)</b>	<b>WHO/FAO (2004)</b>	<b>Afssa (2001a)</b>	<b>IOM (1998)</b>	<b>SCF (1993)</b>	<b>DH (1991)</b>
<b>Infants</b>						
Age (months)	<4	0–6	0–12	0–6		
AI (µg/day)	5	5	6	5	-	-
Age (months)	4–<12	7–12		7–12		
AI (µg/day)	5–10 <sup>(a)</sup>	6	-	6	-	-
<b>Children and adolescents</b>						
Age (years)	1–<4	1–3	1–3	1–3		
AI (µg/day)	10–15 <sup>(a)</sup>	8	12	8	-	-
Age (years)	4–<7	4–6	4–6	4–8		
AI (µg/day)	10–15 <sup>(a)</sup>	12	20	12	-	-
Age (years)	7–<10	7–9	7–9	9–13		
AI (µg/day)	15–20 <sup>(a)</sup>	20	25	20	-	-
Age (years)	10–<13	10–18	10–12	14–18		
AI (µg/day)	20–30 <sup>(a)</sup>	25	35	25	-	-
Age (years)	13–<19		13–15			
AI (µg/day)	25–35 <sup>(a)</sup>	-	45	-	-	-
Age (years)			16–19			
AI (µg/day)	-	-	50	-	-	-
<b>Adults</b>						
Age (years)	≥ 19	≥ 19	19–74	≥ 19	≥ 19	≥ 19
AI (µg/day)	30–60 <sup>(a)</sup>	30	50	30	15–100 <sup>(a)</sup>	10–200 <sup>(a)</sup>
Age (years)	-	-	≥ 75	-	-	-
AI (µg/day)	-	-	60	-	-	-
<b>Pregnancy</b>						
AI (µg/day)	30–60 <sup>(a)</sup>	30	50	30	15–100 <sup>(a)</sup>	-
<b>Lactation</b>						
AI (µg/day)	30–60 <sup>(a)</sup>	35	55	35	15–100 <sup>(a)</sup>	-

368 (a): Acceptable Range of Intakes.

 369 **5. Criteria (endpoints) on which to base Dietary Reference Values**

 370 **5.1. Indicators of biotin requirement**

 371 The Panel considers that data are insufficient to derive the AR for biotin from the use of available  
 372 biomarkers of intake or status for any population group.

 373 **5.2. Biotin intake and health consequences**

374 Data examining the relationship between biotin intake and health outcomes are scarce.

 375 A comprehensive search of the literature published between January 1990 and July 2012 was  
 376 performed as preparatory work to this assessment, to identify relevant health outcomes upon which  
 377 DRVs may potentially be based for biotin (Eeuwijk et al., 2012). Three cross-sectional studies were  
 378 retrieved, which investigated associations between biotin intakes and genome damage (Fenech et al.,  
 379 2005) or blood pressure (Schutte et al., 2003a; Schutte et al., 2003b).

380 The Panel considers that the data available from these studies are very limited and cannot be used for  
381 deriving DRVs for biotin.

### 382 **5.3. Specific considerations for pregnancy and lactation**

383 The Panel notes that higher urinary excretion of 3HIA has been observed in pregnant women  
384 compared to non-pregnant women, while results on urinary biotin excretion were inconsistent (Mock  
385 and Stadler, 1997; Mock DM et al., 1997a; Shibata et al., 2013). However, biotin intake levels were  
386 not reported in these studies and the relevance of these findings with respect to biotin status in  
387 pregnancy is unclear. Another study (Mock et al., 2002b) was of insufficient duration (i.e. two weeks)  
388 to allow conclusions with respect to changes in biomarkers of biotin status (urinary 3HIA and biotin  
389 excretions) in unsupplemented pregnant women.

390 No data on an association between biotin insufficiency in pregnancy and increased incidence of fetal  
391 malformations are available in humans (see Section 2.2).

392 Assuming an average breast milk biotin concentration of 5 µg/L (see Section 2.2.) and an average  
393 breast milk secretion of 0.8 L/day over the first six months of lactation (Butte et al., 2002;  
394 FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009), the Panel notes that mean biotin secretion in milk  
395 is 4 µg/day in fully breastfeeding women.

## 396 **6. Data on which to base Dietary Reference Values**

397 The Panel considers that the available data are insufficient to derive ARs and PRIs for biotin, and  
398 therefore proposes to set an AI for all population groups. The setting of an AI for biotin is based on  
399 observed biotin intakes with a mixed diet and the apparent absence of signs of deficiency in the EU,  
400 suggesting that current intake levels are adequate. There is no indication that the AI should be  
401 different according to sex.

### 402 **6.1. Adults**

403 The Panel chooses the approximate midpoint of the observed median/mean intakes (Appendices C and  
404 D) to set an AI for biotin at 40 µg/day for adults of all ages.

### 405 **6.2. Infants, children and adolescents**

406 Assuming an average breast milk biotin concentration of 5 µg/L and an average breast milk intake of  
407 infants aged 0–6 months of 0.8 L/day (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel,  
408 2009), the estimated biotin intake of infants between zero and six months is 4 µg/day. The AI for  
409 infants over six months of age can be derived by extrapolation from this figure, using allometric  
410 scaling based on reference body weights of the respective age groups<sup>8</sup> to the power of 0.75, in order to  
411 account for the role of biotin in energy metabolism, and rounding to the nearest unit. The AI for  
412 infants aged 7–11 months is set at 6 µg/day.

413 The Panel sets an AI for biotin of 20 µg/day for young children (1–3 years), based on observed  
414 median intakes of this age group. In consideration of the AI set for infants in the second half year of  
415 life, a value at the lower end of the range of observed intakes was chosen. The Panel sets an AI of  
416 25 µg/day for children (4–10 years) and 35 µg/day for adolescents (11–17 years) (Table 3), based on

---

<sup>8</sup> Mean of body weight-for-age at 50<sup>th</sup> percentile of male and female infants aged three and nine months. WHO Multicentre Growth Reference Study Group (World Health Organization), 2006. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. 312 pp.

417 the approximate midpoint of the observed mean/median intakes of the respective age groups  
418 (Appendix B).

### 419 **6.3. Pregnancy and lactation**

420 The Panel considers that data are insufficient to derive a specific AI for biotin in pregnancy. The Panel  
421 considers that the AI for adults of 40 µg/day also applies to pregnant women.

422 Considering average biotin losses through breast milk of 4 µg/day during lactation (Section 5.3.) and  
423 rounding up, the Panel proposes to increase the AI for lactating women to 45 µg/day.

## 424 **CONCLUSIONS**

425 The Panel concludes that there is insufficient evidence to derive an Average Requirement (AR) and a  
426 Population Reference Intake (PRI) for biotin. Suitable data on biotin intake or status and health  
427 outcomes were not available for the setting of DRVs for biotin. Thus, the Panel proposes an Adequate  
428 Intake (AI) for adults based on observed intakes in the EU. It was considered unnecessary to give sex-  
429 specific values. The Panel proposes that the AI for adults also applies to pregnant women. For  
430 lactating women, an increment in the adult AI is proposed, in order to compensate for biotin losses  
431 through secretion of breast milk. An AI is also proposed for infants aged 7–11 months based on  
432 extrapolation from the estimated intake of infants aged zero to six months using allometric scaling,  
433 and for children and adolescents based on observed intakes in the EU.

434 **Table 2:** Summary of Adequate Intakes for biotin

Age	Adequate Intake (µg/day)
7–11 months	6
1–3 years	20
4–10 years	25
11–17 years	35
≥ 18 years <sup>(a)</sup>	40
Lactation	45

435 (a): Including pregnancy.

## 436 **RECOMMENDATIONS FOR RESEARCH**

437 The Panel recommends to review analytical data for biotin in food composition tables, to reflect the  
438 most reliable quantification methods. Dietary biotin intakes should be reassessed accordingly, in order  
439 to ascertain current AIs for biotin.

440 The Panel recommends further research on the dose-response relationships between biotin intake and  
441 functional biomarkers (e.g. markers of activities of biotin-dependent carboxylases) to characterise an  
442 adequate biotin status and to allow the derivation of the requirement of biotin.

## 443 **REFERENCES**

444 Afssa (Agence française de sécurité sanitaire des aliments), 2001a. Apports nutritionnels conseillés  
445 pour la population française [Nutritional recommendations for the French population]. Editions  
446 Tec&Doc, Paris, France, 605 pp.

447 Afssa (Agence française de sécurité sanitaire des aliments), 2001b. Apports nutritionnels conseillés  
448 pour la population française. Editions Tec&Doc, Paris, France, 605 pp.

- 449 Bogusiewicz A, Horvath TD, Stratton SL, Mock DM and Boysen G, 2012. Measurement of  
450 acylcarnitine substrate to product ratios specific to biotin-dependent carboxylases offers a  
451 combination of indicators of biotin status in humans. *Journal of Nutrition*, 142, 1621-1625.
- 452 Butte NF, Lopez-Alarcon MG and Garza C, 2002. Nutrient adequacy of exclusive breastfeeding for  
453 the term infant during the first six months of life. *World Health Organization*, 57 pp.
- 454 D-A-CH (Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung,  
455 Schweizerische Gesellschaft für Ernährungsforschung, Schweizerische Vereinigung für  
456 Ernährung), 2013. Referenzwerte für die Nährstoffzufuhr. Neuer Umschau Buchverlag,  
457 Frankfurt/Main, Germany, 292 pp.
- 458 DGE (Deutschen Gesellschaft für Ernährung e. V.), 2008. Ernährungsbericht 2008. 442 pp.
- 459 DGE (Deutschen Gesellschaft für Ernährung e. V.), 2012. Ernährungsbericht 2012. 432 pp.
- 460 DH (Department of Health), 1991. Dietary Reference Values for food energy and nutrients for the  
461 United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical  
462 Aspects of Food Policy. HMSO, London, UK, 212 pp.
- 463 Eeuwijk J, Oordt A, Terzikhan N and Vonk Noordegraaf-Schouten M, 2012. Literature search and  
464 review related to specific preparatory work in the establishment of Dietary Reference values for  
465 Niacin, Biotin and Vitamin B6. Project developed on the procurement project  
466 CT/EFSA/NUTRI/2011/03. 474 pp.
- 467 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific  
468 Opinion on the appropriate age for introduction of complementary feeding of infants. *EFSA*  
469 *Journal* 2009;7(12):1423, 38 pp. doi:10.2903/j.efsa.2009.1423
- 470 Elmadfa I, Blachfelner J, Freisling H, Haas K, Rust P and Weichselbaum E, 2004. Wiener  
471 Ernährungsbericht 2004. Institut für Ernährungswissenschaften der Universität Wien,  
472 Bundesministerium für Gesundheit, 247 pp.
- 473 Elmadfa I, Freisling H, Nowak V, Hofstädter D, Hasenegger V, Ferge M, Fröhler M, Fritz K, Meyer  
474 AL, Putz P, Rust P, Grossgut R, Mischek D, Kiefer I, Schätzer M, Spanblöchel J, Sturtzel B,  
475 Wagner K-H, Zilberszac A, Vojir F and Plsek K, 2009. Österreichischer Ernährungsbericht 2008.  
476 Institut für Ernährungswissenschaften der Universität Wien, Bundesministerium für Gesundheit,  
477 454 pp.
- 478 Eng WK, Giraud D, Schlegel VL, Wang D, Lee BH and Zemleni J, 2013. Identification and  
479 assessment of markers of biotin status in healthy adults. *British Journal of Nutrition*, 110, 321-329.
- 480 FAO/WHO/UNU (Food and Agriculture Organization of the United Nations/World Health  
481 Organization/United Nations University), 2004. Human energy requirements Report of a Joint  
482 FAO/WHO/UNU Expert Consultation: Rome 17-24 October 2001. FAO food and nutrition  
483 technical report series, 103 pp.
- 484 Fenech M, Baghurst P, Luderer W, Turner J, Record S, Ceppi M and Bonassi S, 2005. Low intake of  
485 calcium, folate, nicotinic acid, vitamin E, retinol, beta-carotene and high intake of pantothenic acid,  
486 biotin and riboflavin are significantly associated with increased genome instability--results from a  
487 dietary intake and micronucleus index survey in South Australia. *Carcinogenesis*, 26, 991-999.
- 488 Ford JE, Zechalko A, Murphy J and Brooke OG, 1983. Comparison of the B vitamin composition of  
489 milk from mothers of preterm and term babies. *Archives of Disease in Childhood*, 58, 367-372.
- 490 Goldsmith SJ, Eitenmiller RR, Feeley RM, Barnhart HM and Maddox FC, 1982. Biotin content of  
491 human milk during early lactational stages. *Nutrition Research*, 2, 579-583.
- 492 Grassl SM, 1992. Human placental brush-border membrane Na(+)-biotin cotransport. *Journal of*  
493 *Biological Chemistry*, 267, 17760-17765.



- 494 Hirano M, Honma K, Daimatsu T, Hayakawa K, Oizumi J, Zaima K and Kanke Y, 1992. Longitudinal  
495 variations of biotin content in human milk. *International Journal for Vitamin and Nutrition*  
496 *Research*, 62, 281-282.
- 497 Horvath TD, Stratton SL, Bogusiewicz A, Owen SN, Mock DM and Moran JH, 2010a. Quantitative  
498 measurement of urinary excretion of 3-hydroxyisovaleryl carnitine by LC-MS/MS as an indicator  
499 of biotin status in humans. *Analytical Chemistry*, 82, 9543-9548.
- 500 Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J and Mock DM, 2010b. Quantitative  
501 measurement of plasma 3-hydroxyisovaleryl carnitine by LC-MS/MS as a novel biomarker of  
502 biotin status in humans. *Analytical Chemistry*, 82, 4140-4144.
- 503 IOM (Institute of Medicine), 1998. *Dietary Reference Intakes for thiamin, riboflavin, niacin, vitamin*  
504 *B6, folate, vitamin b12, pantothenic acid, biotin, and choline*. Food and Nutrition Board. National  
505 Academy Press, Washington, D. C., USA, 591 pp.
- 506 IUNA (Irish Universities Nutrition Alliance), 2011. *National Adult Nutrition Survey*. 40 pp.
- 507 IUNA, (Irish Universities Nutrition Alliance), online-a. *National Children's Food Survey*. Available  
508 online: <http://www.iuna.net>
- 509 IUNA (Irish Universities Nutrition Alliance), online-b. *National Children's Food Survey*. Available  
510 online:<http://www.iuna.net>.
- 511 IUNA, (Irish Universities Nutrition Alliance), online-c. *The National Teens's Food Survey*. Available  
512 online: <http://www.iuna.net>
- 513 IUNA (Irish Universities Nutrition Alliance), online-d. *The National Teens's Food Survey*. Available  
514 online:<http://www.iuna.net>.
- 515 IUNA, (Irish Universities Nutrition Alliance), online-e. *National Preschool Nutrition Survey*.  
516 Available online: <http://www.iuna.net>
- 517 IUNA (Irish Universities Nutrition Alliance), online-f. *National Preschool Nutrition Survey*. Available  
518 online:<http://www.iuna.net>.
- 519 Joffe R, Ozolinš G, Šantare D, Bartkevics V, L. M and Briška I, 2009. *Latvijas iedzīvotāju*  
520 *visaptverošais partikas paterina petījums, 2007-2009*. Nacionalais diagnostikas centrs, Partikas un  
521 veterināra dienesta Partikas centrs, 115 pp.
- 522 Lahely S, Ndaw S, Arella F and Hasselmann C, 1999. Determination of biotin in foods by high-  
523 performance liquid chromatography with post-column derivatization and fluorimetric detection.  
524 *Food Chemistry*, 253-258.
- 525 Mantagos S, Malamitsi-Puchner A, Antsaklis A, Livaniou E, Evangelatos G and Ithakissios DS, 1998.  
526 *Biotin plasma levels of the human fetus*. *Biology of the Neonate*, 74, 72-74.
- 527 Mensink GB, Hesecker H, Richter A, Stahl A, Vohmann C, Fischer J, Kohler S and Six J, 2007.  
528 *Forschungsbericht. Ernährungsstudie als KiGGS-Modul (EsKiMo)*. 137 pp.
- 529 Merten C, Ferrari P, Bakker M, Boss A, Hearty A, Leclercq C, Lindtner O, Tlustos C, Verger P,  
530 Volatier JL and Arcella D, 2011. Methodological characteristics of the national dietary surveys  
531 carried out in the European Union as included in the European Food Safety Authority (EFSA)  
532 Comprehensive European Food Consumption Database. *Food Additives & Contaminants. Part A,*  
533 *Chemistry, Analysis, Control, Exposure & Risk Assessment*, 28, 975-995.
- 534 Mock D, 2006. Biotin. In: *Modern Nutrition in Health and Disease*. 10th Edition. Eds Shils ME, Shike  
535 M, Ross AC, Caballero B and Cousins RJ. Lippincott Williams & Wilkins, Philadelphia, USA,  
536 498-506.
- 537 Mock DM and Malik MI, 1992. Distribution of biotin in human plasma: most of the biotin is not  
538 bound to protein. *American Journal of Clinical Nutrition*, 56, 427-432.

- 539 Mock DM, Mock NI and Dankle JA, 1992. Secretory patterns of biotin in human milk. *Journal of*  
540 *Nutrition*, 122, 546-552.
- 541 Mock DM and Stadler DD, 1997. Conflicting indicators of biotin status from a cross-sectional study of  
542 normal pregnancy. *Journal of the American College of Nutrition*, 16, 252-257.
- 543 Mock DM, Stadler DD, Stratton SL and Mock NI, 1997a. Biotin status assessed longitudinally in  
544 pregnant women. *Journal of Nutrition*, 127, 710-716.
- 545 Mock DM, Mock NI and Stratton SL, 1997b. Concentrations of biotin metabolites in human milk.  
546 *Journal of Pediatrics*, 131, 456-458.
- 547 Mock DM and Dyken ME, 1997. Biotin catabolism is accelerated in adults receiving long-term  
548 therapy with anticonvulsants. *Neurology*, 49, 1444-1447.
- 549 Mock DM, Mock NI, Nelson RP and Lombard KA, 1998. Disturbances in biotin metabolism in  
550 children undergoing long-term anticonvulsant therapy. *Journal of Pediatric Gastroenterology and*  
551 *Nutrition*, 26, 245-250.
- 552 Mock DM, Henrich CL, Carnell N and Mock NI, 2002a. Indicators of marginal biotin deficiency and  
553 repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge.  
554 *American Journal of Clinical Nutrition*, 76, 1061-1068.
- 555 Mock DM, Quirk JG and Mock NI, 2002b. Marginal biotin deficiency during normal pregnancy.  
556 *American Journal of Clinical Nutrition*, 75, 295-299.
- 557 Mock DM, 2005. Marginal biotin deficiency is teratogenic in mice and perhaps humans: a review of  
558 biotin deficiency during human pregnancy and effects of biotin deficiency on gene expression and  
559 enzyme activities in mouse dam and fetus. *The Journal of Nutritional Biochemistry*, 16, 435-437.
- 560 Mock DM, Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Dawson AM,  
561 Spencer HJ, Owen SN, Boysen G and Moran JH, 2011. Urinary excretion of 3-hydroxyisovaleric  
562 acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally  
563 biotin-deficient humans. *Journal of Nutrition*, 141, 1925-1930.
- 564 Mock NI, Malik MI, Stumbo PJ, Bishop WP and Mock DM, 1997. Increased urinary excretion of 3-  
565 hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of  
566 decreased biotin status in experimental biotin deficiency. *American Journal of Clinical Nutrition*,  
567 65, 951-958.
- 568 Mouratidou T, Ford F and Fraser RB, 2006. Validation of a food-frequency questionnaire for use in  
569 pregnancy. *Public Health Nutrition*, 9, 515-522.
- 570 NNR (Nordic Nutrition Recommendations), 2012. Biotin [For Public Consultation]. Nordic Council of  
571 Ministers, 2 pp.
- 572 Said HM, 1999. Biotin bioavailability and estimated average requirement: why bother? *American*  
573 *Journal of Clinical Nutrition*, 69, 352-353.
- 574 Said HM, 2009. Cell and molecular aspects of human intestinal biotin absorption. *Journal of Nutrition*,  
575 139, 158-162.
- 576 Sakurai T, Furukawa M, Asoh M, Kanno T, Kojima T and Yonekubo A, 2005. Fat-soluble and water-  
577 soluble vitamin contents of breast milk from Japanese women. *Journal of Nutritional Science and*  
578 *Vitaminology*, 51, 239-247.
- 579 Salmenpera L, Perheentupa J, Pispala JP and Siimes MA, 1985. Biotin concentrations in maternal  
580 plasma and milk during prolonged lactation. *International Journal for Vitamin and Nutrition*  
581 *Research*, 55, 281-285.
- 582 SCF (Scientific Committee for Food), 1993. Nutrient and energy intakes for the European  
583 Community. Reports of the Scientific Committee for Food, 31st Series. Food - Science and  
584 Technique, European Commission, Luxembourg, 248 pp.

- 585 SCF (Scientific Committee on Food), 2001. Opinion of the Scientific Committee on Food on the  
586 Tolerable Upper Intake Level of biotin. SCF/CS/NUT/UPPLEV/55 Final, 12 pp.
- 587 Schutte AE, Van Rooyen JM, Huisman HW, Kruger HS, Malan NT and De Ridder JH, 2003a. Dietary  
588 markers of hypertension associated with pulse pressure and arterial compliance in black South  
589 African children: the THUSA Bana Study. *Cardiovascular Journal of South Africa*, 14, 81-89.
- 590 Schutte AE, van Rooyen JM, Huisman HW, Kruger HS, Malan NT, De Ridder JH, Transition, Health  
591 During Urbanisation in South Africa in C and Bana C, 2003b. Dietary risk markers that contribute  
592 to the aetiology of hypertension in black South African children: the THUSA BANA study. *Journal*  
593 *of Human Hypertension*, 17, 29-35.
- 594 Sealey WM, Teague AM, Stratton SL and Mock DM, 2004. Smoking accelerates biotin catabolism in  
595 women. *American Journal of Clinical Nutrition*, 80, 932-935.
- 596 Shibata K, Fukuwatari T, Sasaki S, Sano M, Suzuki K, Hiratsuka C, Aoki A and Nagai C, 2013.  
597 Urinary excretion levels of water-soluble vitamins in pregnant and lactating women in Japan.  
598 *Journal of Nutritional Science & Vitaminology*, 59, 178-186.
- 599 Staggs CG, Sealey WM, McCabe BJ, Teague AM and Mock DM, 2004. Determination of the biotin  
600 content of select foods using accurate and sensitive HPLC/avidin binding. *Journal of Food*  
601 *Composition and Analysis*, 17, 767-776.
- 602 Stratton SL, Bogusiewicz A, Mock MM, Mock NI, Wells AM and Mock DM, 2006. Lymphocyte  
603 propionyl-CoA carboxylase and its activation by biotin are sensitive indicators of marginal biotin  
604 deficiency in humans. *American Journal of Clinical Nutrition*, 84, 384-388.
- 605 Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH and  
606 Mock DM, 2011. Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive  
607 indicator of marginal biotin deficiency in humans. *Journal of Nutrition*, 141, 353-358.
- 608 Wang H, Huang W, Fei YJ, Xia H, Yang-Feng TL, Leibach FH, Devoe LD, Ganapathy V and Prasad  
609 PD, 1999. Human placental Na<sup>+</sup>-dependent multivitamin transporter. Cloning, functional  
610 expression, gene structure, and chromosomal localization. *Journal of Biological Chemistry*, 274,  
611 14875-14883.
- 612 WHO Multicentre Growth Reference Study Group (World Health Organization), 2006. WHO Child  
613 Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and  
614 body mass index-for-age: Methods and development. 312 pp.
- 615 WHO/FAO (World Health Organization / Food and Agriculture Organization of the United Nations),  
616 2004. Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO Expert  
617 Consultation, Bangkok, Thailand, 21-30 September 1998. 341 pp.
- 618 Zajkas G, Biro L, Greiner E, Szorad I, Agoston H, Balazs A, Vitrai J, Hermann D, Boros J, Nemeth R,  
619 Keki Z and Martos E, 2007. [Dietary survey in Hungary, 2003-2004. Micronutrients: vitamins].  
620 *Orvosi Hetilap*, 148, 1593-1600.
- 621 Zempleni J, Green GM, Spannagel AW and Mock DM, 1997a. Biliary excretion of biotin and biotin  
622 metabolites is quantitatively minor in rats and pigs. *Journal of Nutrition*, 127, 1496-1500.
- 623 Zempleni J, McCormick DB and Mock DM, 1997b. Identification of biotin sulfone, bisnorbiotin  
624 methyl ketone, and tetranorbiotin-l-sulfoxide in human urine. *American Journal of Clinical*  
625 *Nutrition*, 65, 508-511.
- 626 Zempleni J and Mock DM, 1999a. Advanced analysis of biotin metabolites in body fluids allows a  
627 more accurate measurement of biotin bioavailability and metabolism in humans. *Journal of*  
628 *Nutrition*, 129, 494S-497S.
- 629 Zempleni J and Mock DM, 1999b. Bioavailability of biotin given orally to humans in pharmacologic  
630 doses. *American Journal of Clinical Nutrition*, 69, 504-508.

631 Zempleni J and Mock DM, 1999c. Biotin biochemistry and human requirements. The Journal of  
632 Nutritional Biochemistry, 10, 128-138.

633 Zempleni J and Mock DM, 2000. Marginal biotin deficiency is teratogenic. Proceedings of the Society  
634 for Experimental Biology and Medicine, 223, 14-21.

635

636

637 APPENDICES

638 Appendix A. Biotin concentration of human milk from healthy mothers of term infants

Reference	Number of women (number of samples)	Country	Total maternal intake	Plasma concentration	Stage of lactation	Biotin concentration		Method of analysis
			( $\mu\text{g/day}$ ) Mean (range)	( $\text{ng/L}$ ) Mean (range)		( $\mu\text{g/L}$ ) Mean $\pm$ SD	range	
Sakurai et al. (2005)	(6)	Japan	Not reported <sup>(a)</sup>	Not reported	6–10 days	2.8 $\pm$ 2.7	n.a.	Microbiological assay ( <i>Lactobacillus arabinosus</i> )
	(6)				11–20 days	5.9 $\pm$ 4.0		
	(34)				21–89 days	5.8 $\pm$ 2.4		
	(34)				90–180 days	4.8 $\pm$ 1.7		
	(34)				181–365 days	4.2 $\pm$ 1.7		
	(60)				Summer	4.7 $\pm$ 2.2		
	(69)				Winter	5.2 $\pm$ 2.3		
(129)	Overall	5.0 $\pm$ 2.3						
Mock DM et al. (1997b)	15	USA	Dietary supplement containing < 4 $\mu\text{g}$ (~10 % of daily intake)	Not reported	8 days	~ 2.0	n.a.	HPLC avidin-binding assay
					36 days	~ 6.8		
Hirano et al. (1992)	38 (102)	Japan	Not reported <sup>(b)</sup>	Not reported	0–5 days	0.8 $\pm$ 0.6	n.a.	Microbiological assay ( <i>Lactobacillus plantarum</i> , ATCC 8014)
					6–14 days	1.8 $\pm$ 1.4		
					15–24 days	5.2 $\pm$ 2.1		
Salmenpera et al. (1985)	200	Finland	Not reported <sup>(c)</sup>	250 <sup>(d)</sup>	0 months	n.d.	n.a.	Microbiological assay ( <i>Lactobacillus plantarum</i> , ATCC 8014)
	n.a				2 months	4.5 <sup>(d)</sup>		
	116				6 months	4.5 <sup>(d)</sup>		
	36				9 months	4.5 <sup>(d)</sup>		
				(142–1 090)				
Ford et al. (1983)	35	UK	Not reported <sup>(b)</sup>	Not reported	1–5 days	0.21	0.02–0.83	‘Standard microbiological methods’
					6–15 days	2.21	0.05–8.0	
					16–244 days	5.30	0.60–12.0	
Goldsmith et al. (1982)	84	USA	Not reported <sup>(b)</sup>	Not reported	3–8 days	0.7 $\pm$ 0.9	0.0–7.2	Microbiological assay ( <i>Lactobacillus plantarum</i> , ATCC 8014)
	67				10–14 days	3.0 $\pm$ 2.2	0.1–11.8	
	64				30–47 days	4.7 $\pm$ 2.2	0.5–14.1	

639 (a): Not taking supplements

640 (b): No indication of supplementation

641 (c): No supplementation during lactation or pregnancy

642 (d): Geometric mean

643 n.a., not available; n.d, non detectable.

644

645 **Appendix B. Biotin intake among children and adolescents in European countries**

Country	Reference	Dietary assessment method (year of survey)(a)	Age (years)	n	Mean (µg/day)	SD	Median (µg/day)	P5 – P95
<b>Boys</b>								
<b>Austria</b>	Elmadfa et al. (2009)	Seven-day record (2003)	7–9	n.a.	34	n.a.	n.a.	n.a.
			10–12	n.a.	35	n.a.	n.a.	n.a.
			13–15	n.a.	34	n.a.	n.a.	n.a.
		Three-day record (2007–2008)	7–9	148	33	n.a.	n.a.	n.a.
			10–12	155	32	n.a.	n.a.	n.a.
			13–15	86	33	n.a.	n.a.	n.a.
		24-hour recall (2004) (Berufsschüler/AHS-schüler) (from Vienna)	14–19	35/47	35/47	n.a.	n.a.	n.a.
<b>Germany</b>	DGE (2008) DGE (2008) Mensink et al. (2007) Mensink et al. (2007) DGE (2012)	Three-day record (2001–2002)	1– < 4	242	n.a.	n.a.	30.9	n.a.
			4– < 5	242	n.a.	n.a.	28.2	n.a.
		Three-day record (2006)	6–11	626	48.2	n.a.	38.2	22.2–119.4
		Dietary history (over the last four weeks) (2006)	12–17	622	96.7	n.a.	63.5	27.9–265.6
		Two non-consecutive 24-hour recalls (2005–2006)	15–19	506	n.a.	n.a.	45.0	n.a.
<b>Ireland</b>	IUNA (online-a) IUNA (online-b) IUNA (online-c) IUNA (online-d)	Seven-day record (2003–2004)	5–8	145	26.0	23.8	19.7	9.2–65.4
			9–12	148	27.8	22.0	24.2	9.9–57.7
		Seven-day record (2005–2006)	13–14	95	34.4	34.1	25.0	11.0–119.5
		Seven-day record (2005–2006)	15–17	129	40.5	41.5	27.0	14.0–131.5
<b>Girls</b>								
<b>Austria</b>	Elmadfa et al. (2009)	Seven-day record (2003)	7–9	n.a.	30	n.a.	n.a.	n.a.
			10–12	n.a.	33	n.a.	n.a.	n.a.
			13–15	n.a.	31	n.a.	n.a.	n.a.
		Three-day record (2007–2008)	7–9	175	31	n.a.	n.a.	n.a.
			10–12	152	29	n.a.	n.a.	n.a.
			13–15	64	27	n.a.	n.a.	n.a.
		24-hour recall (2004) (Berufsschüler/AHS-schüler) (from Vienna)	14–19	28/39	28/39	n.a.	n.a.	n.a.



Country	Reference	Dietary assessment method (year of survey)(a)	Age (years)	n	Mean (µg/day)	SD	Median (µg/day)	P5 – P95
<b>Germany</b>	DGE (2008)	Three-day record (2001–2002)	1– < 4	246	n.a.	n.a.	25.4	n.a.
	DGE (2008)	Three-day record (2001–2002)	4– < 5	246	n.a.	n.a.	29.3	n.a.
	Mensink et al. (2007)	Three-day record (2006)	6–11	608	44.7	n.a.	35.7	17.9–106.5
	Mensink et al. (2007)	Dietary history (over the last four weeks) (2006)	12–17	650	84.4	n.a.	49.5	22.8–266.8
	DGE (2012)	Two non-consecutive 24-hour recalls (2005–2006)	15–19	536	n.a.	n.a.	36.0	n.a.
<b>Ireland</b>	IUNA (online-b)	Seven-day record (2003–2004)	5–8	151	23.3	26.5	19.1	9.9–52.2
	IUNA (online-b)	Seven-day record (2003–2004)	9–12	150	24.4	24.3	19.6	9.1–61.5
	IUNA (online-d)	Seven-day record (2005–2006)	13–14	93	27.5	50.1	16.5	7.7–79.1
	IUNA (online-d)	Seven-day record (2005–2006)	15–17	124	24.6	20.4	20.5	6.9–66.0
<b>Both sexes</b>								
<b>Ireland</b>	(IUNA, online-f)	Four-day weighed dietary record (2010–2011)	1–4	500	22.9	16.3	19.3	9.9–53.4

646 (a): supplements excluded.  
 647 n.a., not available.  
 648

649 **Appendix C. Biotin intake among adults aged ~ 19–65 years in European countries**

Country	Reference	Dietary assessment method (year of survey)(a)	Age (years)	n	Mean (µg/day)	SD	Median	P5 – P95
<b>Men</b>								
<b>Austria</b>	Elmadfa et al. (2009)	24-hour recall	18–25	93	50	n.a.	n.a.	n.a.
			25–51	541	44	n.a.	n.a.	n.a.
			51–64	144	42	n.a.	n.a.	n.a.
<b>Germany</b>	DGE (2012)	Two non-consecutive 24-hour recalls (2005–2006)	19–24	469	n.a.	n.a.	46	n.a.
			25–34	614	n.a.	n.a.	48	n.a.
			35–50	1 946	n.a.	n.a.	48	n.a.
			51–64	1 460	n.a.	n.a.	47	n.a.
<b>Hungary</b>	Zajkas et al. (2007)	Three-day record (2003–2004)	18–34	136	32.5	8.4	n.a.	n.a.
			35–59	199	32.6	9.3	n.a.	n.a.
<b>Ireland</b>	IUNA (2011)	Four-day record (2008–2010)	18–64	634	42	18	40	19-72
<b>Women</b>								
<b>Austria</b>	Elmadfa et al. (2009)	24-hour recall	18–25	187	41			
			25–51	959	42			
			51–64	199	43			
<b>Germany</b>	DGE (2012)	Two non-consecutive 24-hour recalls (2005–2006)	19–24	486	n.a.	n.a.	39	n.a.
			25–34	852	n.a.	n.a.	42	n.a.
			35–50	2 648	n.a.	n.a.	41	n.a.
			51–64	1 740	n.a.	n.a.	41	n.a.
<b>Hungary</b>	Zajkas et al. (2007)	Three-day record (2003–2004)	18–34	176	26.9	8.6	n.a.	n.a.
			35–59	295	26.2	8.0	n.a.	n.a.
<b>Ireland</b>	IUNA (2011)	Four-day record (2008–2010)	18–64	640	32	17	29	13-58
<b>Both sexes</b>								
<b>Latvia</b>	Joffe et al. (2009)	Two non-consecutive 24-hour dietary recalls + food frequency questionnaire (2008)	17–26	378	34.3	n.a.	n.a.	n.a.
			27–36	206	36.3	n.a.	n.a.	n.a.
			37–46	272	35.0	n.a.	n.a.	n.a.
			47–56	304	34.8	n.a.	n.a.	n.a.
			57–64	217	45.4	n.a.	n.a.	n.a.

650 (a): supplements excluded  
651 n.a., not available.

652

653 **Appendix D. Biotin intake among adults aged ~ 65 years and over in European countries**

Country	Reference	Dietary assessment method (year of survey)(a)	Age (years)	n	Mean (µg/day)	SD	Median (µg/day)	P5 – P95
<b>Men</b>								
<b>Austria</b>	Elmadfa et al. (2009)	Three-day record (2007–2008)	≥ 55	121	34	n.a.	n.a.	n.a.
<b>Germany</b>	DGE (2012)	Two non-consecutive 24-hour recalls (2005-2006)	65–80	1 165	n.a.	n.a.	43	n.a.
<b>Hungary</b>	Zajkas et al. (2007)	Three-day record (2003–2004)	≥ 60	138	29.1	8.5	n.a.	n.a.
<b>Ireland</b>	IUNA (2011)	Four-day record (2008–2010)	≥ 65	106	40	19	36	17–68
<b>Women</b>								
<b>Austria</b>	Elmadfa et al. (2009)	Three-day record (2007–2008)	≥ 55	302	34	n.a.	n.a.	n.a.
<b>Germany</b>	DGE (2012)	Two non-consecutive 24-hour recalls (2005–2006)	65–80	1 331	n.a.	n.a.	39	n.a.
<b>Hungary</b>	Zajkas et al. (2007)	Three-day record (2003–2004)	≥ 60	235	24.5	7.8	n.a.	n.a.
<b>Ireland</b>	IUNA (2011)	Four-day record (2008–2010)	≥ 65	120	37	28	32	18–61

654 (a): supplements excluded  
 655 n.a., not available.

656 **ABBREVIATIONS**

ACC	Acetyl-CoA Carboxylase
Afssa	Agence française de sécurité sanitaire des aliments
AI	Adequate Intake
AR	Average Requirement
CoA	Coenzyme A
COMA	Committee on Medical Aspects of Food Policy
D-A-CH	Deutschland- Austria- Confoederatio Helvetica
DGE	Deutschen Gesellschaft für Ernährung Dietary Reference Value
DH	Department of Health
DRV	Dietary Reference Value
EC	European Commission
EFSA	European Food Safety Authority
EU	European Union
FAO	Food and Agriculture Organization
FFQ	Food Frequency Questionnaire
3HIA	3-Hydroxyisovaleric Acid
HPLC	High Performance Liquid Chromatography
IOM	U.S. Institute of Medicine of the National Academy of Sciences
IUNA	Irish Universities Nutrition Alliance
IUPAC	International Union of Pure and Applied Chemistry
MCC	$\beta$ -Methylcrotonyl-CoA Carboxylase
mRNA	messenger ribonucleic acid
NNR	Nordic Nutrition Recommendations
PC	Pyruvate Carboxylase
PCC	Propionyl-CoA Carboxylase
SCF	Scientific Committee for Food

SD	Standard Deviation
UL	Tolerable Upper Intake Level
UNU	United Nations University
WHO	World Health Organization

657